<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054481</url>
  </required_header>
  <id_info>
    <org_study_id>1311.2</org_study_id>
    <secondary_id>2012-004384-48</secondary_id>
    <nct_id>NCT02054481</nct_id>
  </id_info>
  <brief_title>BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab</brief_title>
  <official_title>A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The overall purpose of this trial is to assess clinical efficacy and safety of different
      subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to
      select doses for further clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage of participants who achieved ≥90% reduction from baseline in Psoriasis Area and Severity Index score (PASI90) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of ≥75% Reduction From Baseline in PASI Score (PASI75) at Weeks 12 and 24</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>Percentage of participants who achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index score (PASI75) at Weeks 12 and 24.
PASI score ranges from 0 (best) to 72 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage of participants who achieved 100% reduction from baseline in Psoriasis Area and Severity Index score (PASI100) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage of participants who achieved ≥50% reduction from baseline in Psoriasis Area and Severity Index score (PASI50) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of PASI90 at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants who achieved PASI90 at Week 24.
PASI score ranges from 0 (best) to 72 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in PASI Score From Baseline at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage change in Psoriasis Area and Severity Index (PASI) from baseline at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of sPGA Clear or Almost Clear at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of participants who achieved static Physician Global Assessment (sPGA) clear or almost clear at Week 12.
sPGA is assessed on a six-point scale from 0 (clear) to 5 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of PASI50 Response</measure>
    <time_frame>From first drug administration until end of follow-up period, up to 48 weeks</time_frame>
    <description>Time to loss of PASI50 response.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 655066 s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 655066 s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 655066 s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ustekinumab s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066</intervention_name>
    <description>Medium dose</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066</intervention_name>
    <description>High dose</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066</intervention_name>
    <description>Low dose</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Body Mass Index (BMI) &gt;/= 18.5 and &lt; 40 kg/m²

          -  Patients with stable moderate to severe chronic plaque-type psoriasis with or without
             psoriatic arthritis involving &gt;/= 10% body surface area, with disease severity PASI
             &gt;/= 12 and sPGA score of moderate and above (score of at least 3) at screening visit
             and visit 2 (randomisation), as assessed by the investigator

          -  Psoriasis disease duration of at least 6 months prior to screening, as assessed by the
             investigator

          -  Patients must be candidates for systemic psoriasis treatment or phototherapy, as
             assessed by the investigator

          -  Patients must be suitable candidates for ustekinumab (Stelara®) therapy as given in
             the local labelling

          -  Patient must give informed consent and sign an approved consent form prior to any
             study procedures in accordance with GCP and local legislation

        Exclusion criteria:

          -  Patients with guttate, erythrodermic, or pustular psoriasis and patients with
             drug-induced psoriasis, as diagnosed by the investigator

          -  Evidence of current or previous clinically significant disease, medical condition
             other than psoriasis, or finding of the medical examination (including vital signs and
             ECG), that in the opinion of the investigator, would compromise the safety of the
             patient or the quality of the data. This criterion provides an opportunity for the
             investigator to exclude patients based on clinical judgment, even if other eligibility
             criteria are satisfied. (Psoriatic arthritis is not considered an exclusion criterion)

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders, diseases of the central nervous system (such as
             epilepsy) or psychiatric disorders or neurological disorders, or history of
             orthostatic hypotension, fainting spells or blackouts, that in the investigator's
             judgement, could jeopardize the safe conduct of the study.

          -  Clinically important acute or chronic infections including hepatitis and HIV.

        With regards to tuberculosis the following applies:

        Have signs or symptoms suggestive of current active or latent TB upon medical history,
        physical examination and/or a chest radiograph (both posterior-anterior and lateral views,
        taken within 3 months prior to the first administration of study drug and read by a
        qualified radiologist).

        Have history of latent or active TB prior to screening, except for patients who have
        documentation of having completed an adequate treatment regimen at least 6 months prior to
        the first administration of study agent.

        Have positive IGRA testing (QuantiFERON-TB Gold) within 2 months prior to or during
        screening, in which active TB has not been ruled out, except for patients with history of
        latent TB and documentation of having completed an adequate treatment regimen at least 6
        months prior to the first administration of study agent.

          -  Have had a live vaccination &lt;/= 12 weeks prior to randomisation (visit 2). Patients
             must agree not to receive a live vaccination during the study. No BCG vaccines should
             be given for one year prior to randomisation (visit 2), during the study and for one
             year after last administration of study drug (according to the Stelara® SPC).

          -  History of clinically significant hypersensitivity to a systemically administered
             biologic agent or its excipients

          -  History of malignancy in the past 5 years or suspicion of active malignant disease
             except treated cutaneous squamous cell or basal cell carcinoma

          -  Has received any therapeutic agent directly targeted to IL-12, IL-23 (including
             ustekinumab (Stelara®))

          -  Use of biologic agents within 12 weeks (infliximab, etanercept, adalimumab, other
             biologics) prior to treatment, systemic anti-psoriatic medications or phototherapy
             within 4 weeks prior to treatment, or topical anti-psoriasis medications within 2
             weeks prior to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1311.2.10010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington Hts</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.20004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.2.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <results_first_submitted>July 29, 2016</results_first_submitted>
  <results_first_submitted_qc>July 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2016</results_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participant flow shows disposition at the end of treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BI 655066 18 mg</title>
          <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
        </group>
        <group group_id="P2">
          <title>BI 655066 90 mg</title>
          <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
        </group>
        <group group_id="P3">
          <title>BI 655066 180 mg</title>
          <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
        </group>
        <group group_id="P4">
          <title>Stelara</title>
          <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set (SAF) which Included all randomised patients who received at least 1 dose of trial medication and was based on the first treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>BI 655066 18 mg</title>
          <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
        </group>
        <group group_id="B2">
          <title>BI 655066 90 mg</title>
          <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
        </group>
        <group group_id="B3">
          <title>BI 655066 180 mg</title>
          <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
        </group>
        <group group_id="B4">
          <title>Stelara</title>
          <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="14.2"/>
                    <measurement group_id="B2" value="49.3" spread="13.3"/>
                    <measurement group_id="B3" value="44.9" spread="14.0"/>
                    <measurement group_id="B4" value="45.4" spread="12.1"/>
                    <measurement group_id="B5" value="45.9" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12</title>
        <description>Percentage of participants who achieved ≥90% reduction from baseline in Psoriasis Area and Severity Index score (PASI90) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) which included all randomised patients who received at least 1 dose of trial medication and was based on the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 655066 18 mg</title>
            <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
          </group>
          <group group_id="O2">
            <title>BI 655066 90 mg</title>
            <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
          </group>
          <group group_id="O3">
            <title>BI 655066 180 mg</title>
            <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
          </group>
          <group group_id="O4">
            <title>BI 655066 90+180 mg</title>
            <description>90 mg BI 655066 or 180mg BI 655066 administered by subcutaneous injection at Weeks 0, 4 and 16, plus matching placebos.</description>
          </group>
          <group group_id="O5">
            <title>Stelara</title>
            <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12</title>
          <description>Percentage of participants who achieved ≥90% reduction from baseline in Psoriasis Area and Severity Index score (PASI90) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
          <population>Full Analysis Set (FAS) which included all randomised patients who received at least 1 dose of trial medication and was based on the randomised treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="19.1" upper_limit="48.5"/>
                    <measurement group_id="O2" value="73.2" lower_limit="57.1" upper_limit="85.8"/>
                    <measurement group_id="O3" value="81.0" lower_limit="65.9" upper_limit="91.4"/>
                    <measurement group_id="O4" value="77.1" lower_limit="66.6" upper_limit="85.6"/>
                    <measurement group_id="O5" value="40.0" lower_limit="24.9" upper_limit="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for weight (=&lt;100kg vs &gt;100kg) &amp; prior exposure to 2 or more tumour necrosis factor antagonists with discontinuation due to lack of efficacy</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>36.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.0</ci_lower_limit>
            <ci_upper_limit>53.8</ci_upper_limit>
            <estimate_desc>Difference calculated as BI 90+180 mg minus Stelara</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of ≥75% Reduction From Baseline in PASI Score (PASI75) at Weeks 12 and 24</title>
        <description>Percentage of participants who achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index score (PASI75) at Weeks 12 and 24.
PASI score ranges from 0 (best) to 72 (worst).</description>
        <time_frame>Baseline, Week 12 and Week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 655066 18 mg</title>
            <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
          </group>
          <group group_id="O2">
            <title>BI 655066 90 mg</title>
            <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
          </group>
          <group group_id="O3">
            <title>BI 655066 180 mg</title>
            <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
          </group>
          <group group_id="O4">
            <title>BI 655066 90+180 mg</title>
            <description>90 mg BI 655066 or 180mg BI 655066 administered by subcutaneous injection at Weeks 0, 4 and 16, plus matching placebos.</description>
          </group>
          <group group_id="O5">
            <title>Stelara</title>
            <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of ≥75% Reduction From Baseline in PASI Score (PASI75) at Weeks 12 and 24</title>
          <description>Percentage of participants who achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index score (PASI75) at Weeks 12 and 24.
PASI score ranges from 0 (best) to 72 (worst).</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" lower_limit="51.5" upper_limit="80.9"/>
                    <measurement group_id="O2" value="97.6" lower_limit="87.1" upper_limit="99.9"/>
                    <measurement group_id="O3" value="90.5" lower_limit="77.4" upper_limit="97.3"/>
                    <measurement group_id="O4" value="94.0" lower_limit="86.5" upper_limit="98.0"/>
                    <measurement group_id="O5" value="77.5" lower_limit="61.5" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" lower_limit="39.9" upper_limit="70.9"/>
                    <measurement group_id="O2" value="92.7" lower_limit="80.1" upper_limit="98.5"/>
                    <measurement group_id="O3" value="92.9" lower_limit="80.5" upper_limit="98.5"/>
                    <measurement group_id="O4" value="92.8" lower_limit="84.9" upper_limit="97.3"/>
                    <measurement group_id="O5" value="70.0" lower_limit="53.5" upper_limit="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0355</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for weight (=&lt;100kg vs &gt;100kg) &amp; prior exposure to 2 or more tumour necrosis factor antagonists with discontinuation due to lack of efficacy</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
            <estimate_desc>Difference calculated as BI 90+180 mg minus Stelara</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0062</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for weight (=&lt;100kg vs &gt;100kg) &amp; prior exposure to 2 or more tumour necrosis factor antagonists with discontinuation due to lack of efficacy</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>21.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.0</ci_lower_limit>
            <ci_upper_limit>36.2</ci_upper_limit>
            <estimate_desc>Difference calculated as BI 90+180 mg minus Stelara</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 12</title>
        <description>Percentage of participants who achieved 100% reduction from baseline in Psoriasis Area and Severity Index score (PASI100) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 655066 18 mg</title>
            <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
          </group>
          <group group_id="O2">
            <title>BI 655066 90 mg</title>
            <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
          </group>
          <group group_id="O3">
            <title>BI 655066 180 mg</title>
            <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
          </group>
          <group group_id="O4">
            <title>BI 655066 90+180 mg</title>
            <description>90 mg BI 655066 or 180mg BI 655066 administered by subcutaneous injection at Weeks 0, 4 and 16, plus matching placebos.</description>
          </group>
          <group group_id="O5">
            <title>Stelara</title>
            <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 12</title>
          <description>Percentage of participants who achieved 100% reduction from baseline in Psoriasis Area and Severity Index score (PASI100) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="5.3" upper_limit="27.9"/>
                    <measurement group_id="O2" value="41.5" lower_limit="26.3" upper_limit="57.9"/>
                    <measurement group_id="O3" value="50.0" lower_limit="34.2" upper_limit="65.8"/>
                    <measurement group_id="O4" value="45.8" lower_limit="34.8" upper_limit="57.1"/>
                    <measurement group_id="O5" value="17.5" lower_limit="7.3" upper_limit="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for weight (=&lt;100kg vs &gt;100kg) &amp; prior exposure to 2 or more tumour necrosis factor antagonists with discontinuation due to lack of efficacy</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>27.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.3</ci_lower_limit>
            <ci_upper_limit>42.9</ci_upper_limit>
            <estimate_desc>Difference calculated as BI 90+180 mg minus Stelara</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 12</title>
        <description>Percentage of participants who achieved ≥50% reduction from baseline in Psoriasis Area and Severity Index score (PASI50) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 655066 18 mg</title>
            <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
          </group>
          <group group_id="O2">
            <title>BI 655066 90 mg</title>
            <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
          </group>
          <group group_id="O3">
            <title>BI 655066 180 mg</title>
            <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
          </group>
          <group group_id="O4">
            <title>BI 655066 90+180 mg</title>
            <description>90 mg BI 655066 or 180mg BI 655066 administered by subcutaneous injection at Weeks 0, 4 and 16, plus matching placebos.</description>
          </group>
          <group group_id="O5">
            <title>Stelara</title>
            <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 12</title>
          <description>Percentage of participants who achieved ≥50% reduction from baseline in Psoriasis Area and Severity Index score (PASI50) at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="80.9" upper_limit="98.5"/>
                    <measurement group_id="O2" value="100.0" lower_limit="91.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="95.2" lower_limit="83.8" upper_limit="99.4"/>
                    <measurement group_id="O4" value="97.6" lower_limit="91.6" upper_limit="99.7"/>
                    <measurement group_id="O5" value="87.5" lower_limit="73.2" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0706</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for weight (=&lt;100kg vs &gt;100kg) &amp; prior exposure to 2 or more tumour necrosis factor antagonists with discontinuation due to lack of efficacy</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>21.1</ci_upper_limit>
            <estimate_desc>Difference calculated as BI 90+180 mg minus Stelara</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of PASI90 at Week 24</title>
        <description>Percentage of participants who achieved PASI90 at Week 24.
PASI score ranges from 0 (best) to 72 (worst).</description>
        <time_frame>Week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 655066 18 mg</title>
            <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
          </group>
          <group group_id="O2">
            <title>BI 655066 90 mg</title>
            <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
          </group>
          <group group_id="O3">
            <title>BI 655066 180 mg</title>
            <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
          </group>
          <group group_id="O4">
            <title>BI 655066 90+180 mg</title>
            <description>90 mg BI 655066 or 180mg BI 655066 administered by subcutaneous injection at Weeks 0, 4 and 16, plus matching placebos.</description>
          </group>
          <group group_id="O5">
            <title>Stelara</title>
            <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of PASI90 at Week 24</title>
          <description>Percentage of participants who achieved PASI90 at Week 24.
PASI score ranges from 0 (best) to 72 (worst).</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="17.2" upper_limit="46.1"/>
                    <measurement group_id="O2" value="65.9" lower_limit="49.4" upper_limit="79.9"/>
                    <measurement group_id="O3" value="85.7" lower_limit="71.5" upper_limit="94.6"/>
                    <measurement group_id="O4" value="75.9" lower_limit="65.3" upper_limit="84.6"/>
                    <measurement group_id="O5" value="55.0" lower_limit="38.5" upper_limit="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0300</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for weight (=&lt;100kg vs &gt;100kg) &amp; prior exposure to 2 or more tumour necrosis factor antagonists with discontinuation due to lack of efficacy</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>19.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>37.7</ci_upper_limit>
            <estimate_desc>Difference calculated as BI 90+180 mg minus Stelara</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in PASI Score From Baseline at Week 12</title>
        <description>Percentage change in Psoriasis Area and Severity Index (PASI) from baseline at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 655066 18 mg</title>
            <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
          </group>
          <group group_id="O2">
            <title>BI 655066 90 mg</title>
            <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
          </group>
          <group group_id="O3">
            <title>BI 655066 180 mg</title>
            <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
          </group>
          <group group_id="O4">
            <title>BI 655066 90+180 mg</title>
            <description>90 mg BI 655066 or 180mg BI 655066 administered by subcutaneous injection at Weeks 0, 4 and 16, plus matching placebos.</description>
          </group>
          <group group_id="O5">
            <title>Stelara</title>
            <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in PASI Score From Baseline at Week 12</title>
          <description>Percentage change in Psoriasis Area and Severity Index (PASI) from baseline at Week 12.
PASI score ranges from 0 (best) to 72 (worst).</description>
          <population>FAS including patients with available data.</population>
          <units>Percentage of PASI score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.7" spread="19.5"/>
                    <measurement group_id="O2" value="-93.4" spread="7.7"/>
                    <measurement group_id="O3" value="-90.7" spread="23.1"/>
                    <measurement group_id="O4" value="-92.1" spread="17.1"/>
                    <measurement group_id="O5" value="-82.1" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of sPGA Clear or Almost Clear at Week 12</title>
        <description>Percentage of participants who achieved static Physician Global Assessment (sPGA) clear or almost clear at Week 12.
sPGA is assessed on a six-point scale from 0 (clear) to 5 (severe).</description>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 655066 18 mg</title>
            <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
          </group>
          <group group_id="O2">
            <title>BI 655066 90 mg</title>
            <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
          </group>
          <group group_id="O3">
            <title>BI 655066 180 mg</title>
            <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
          </group>
          <group group_id="O4">
            <title>BI 655066 90+180 mg</title>
            <description>90 mg BI 655066 or 180mg BI 655066 administered by subcutaneous injection at Weeks 0, 4 and 16, plus matching placebos.</description>
          </group>
          <group group_id="O5">
            <title>Stelara</title>
            <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of sPGA Clear or Almost Clear at Week 12</title>
          <description>Percentage of participants who achieved static Physician Global Assessment (sPGA) clear or almost clear at Week 12.
sPGA is assessed on a six-point scale from 0 (clear) to 5 (severe).</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" lower_limit="46.7" upper_limit="77.0"/>
                    <measurement group_id="O2" value="90.2" lower_limit="76.9" upper_limit="97.3"/>
                    <measurement group_id="O3" value="90.5" lower_limit="77.4" upper_limit="97.3"/>
                    <measurement group_id="O4" value="90.4" lower_limit="81.9" upper_limit="95.7"/>
                    <measurement group_id="O5" value="67.5" lower_limit="50.9" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0072</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for weight (=&lt;100kg vs &gt;100kg) &amp; prior exposure to 2 or more tumour necrosis factor antagonists with discontinuation due to lack of efficacy</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>21.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.7</ci_lower_limit>
            <ci_upper_limit>36.6</ci_upper_limit>
            <estimate_desc>Difference calculated as BI 90+180 mg minus Stelara</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of PASI50 Response</title>
        <description>Time to loss of PASI50 response.</description>
        <time_frame>From first drug administration until end of follow-up period, up to 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 655066 18 mg</title>
            <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
          </group>
          <group group_id="O2">
            <title>BI 655066 90 mg</title>
            <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
          </group>
          <group group_id="O3">
            <title>BI 655066 180 mg</title>
            <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
          </group>
          <group group_id="O4">
            <title>BI 655066 90+180 mg</title>
            <description>90 mg BI 655066 or 180mg BI 655066 administered by subcutaneous injection at Weeks 0, 4 and 16, plus matching placebos.</description>
          </group>
          <group group_id="O5">
            <title>Stelara</title>
            <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of PASI50 Response</title>
          <description>Time to loss of PASI50 response.</description>
          <population>FAS</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253" lower_limit="212" upper_limit="285"/>
                    <measurement group_id="O2" value="NA">Not calculable due to low number of patients with events</measurement>
                    <measurement group_id="O3" value="NA">Not calculable due to low number of patients with events</measurement>
                    <measurement group_id="O4" value="NA">Not calculable due to low number of patients with events</measurement>
                    <measurement group_id="O5" value="338" lower_limit="253">Not calculable due to low number of patients with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.1844</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 15 weeks after the last drug administration, up to 231 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BI 655066 18 mg</title>
          <description>18 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed by two placebo matching BI 655066 injections each at Weeks 4 and 16.</description>
        </group>
        <group group_id="E2">
          <title>BI 655066 90 mg</title>
          <description>90 mg BI 655066 administered by subcutaneous injection plus two placebo matching BI 655066 injections at Week 0, followed 90mg BI 655066 plus one placebo matching BI 655066 injection at Weeks 4 and 16.</description>
        </group>
        <group group_id="E3">
          <title>BI 655066 180 mg</title>
          <description>180 mg BI 655066 administered by subcutaneous injection as two injections plus a placebo matching BI 655066 injection at Week 0, followed 180 mg BI 655066 administered as two injections at Weeks 4 and 16.</description>
        </group>
        <group group_id="E4">
          <title>Stelara</title>
          <description>Stelara administered by subcutaneous injection plus two saline injections at Week 0, Stelara injection plus one saline injection at Weeks 4 and 16. Stelara dose was 45 mg for patients with body weight ≤100 kg at randomisation or 90 mg for patients with body weight &gt;100 kg at randomisation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

